Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Proteomics International Laboratories Ltd News & Analysis
video
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,316.70 | 98.30 | -1.17% |
| CAC 40 | 7,274.48 | 19.89 | -0.27% |
| DAX 40 | 19,884.75 | 85.11 | -0.43% |
| Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
| FTSE 100 | 8,084.61 | 20.71 | -0.26% |
| HKSE | 19,720.70 | 31.81 | -0.16% |
| NASDAQ | 19,572.60 | 199.83 | 1.03% |
| Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
| NZX 50 Index | 12,904.11 | 149.96 | 1.18% |
| S&P 500 | 5,930.85 | 63.77 | 1.09% |
| S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
| SSE Composite Index | 3,368.07 | 1.96 | -0.06% |